Entering text into the input field will update the search result below

NuCana falls on decision to halt late-stage study for biliary tract cancer

Mar. 03, 2022 8:31 AM ETNuCana plc (NCNA)By: Dulan Lokuwithana, SA News Editor

Cancer cells vis

koto_feja/E+ via Getty Images

  • The ADRs of British biotech, NuCana (NASDAQ:NCNA) are trading ~55% lower in the pre-market Thursday after the company announced its decision to discontinue Phase 3 trial for Acelarin in biliary tract cancer.
  • The study named NuTide:121 was

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.